-+ 0.00%
-+ 0.00%
-+ 0.00%

Chardan Capital Maintains Buy on 4D Molecular Therapeutics, Lowers Price Target to $25

Benzinga·10/06/2026 12:26:41
Listen to the news
Chardan Capital analyst Gautam Chukka maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and lowers the price target from $26 to $25.